Advancement in pharmacokinetic mechanisms of herb-drug interaction

Abstract

Abstract: Recently, there is a dramatic increase in the combination use of traditional Chinese medicine and western drug, causing various drug interactions and adverse effects. This combination can not only change physiochemical properties of the related drugs and physiological nature of human body, but regulate expression and function of drug metabolizing enzymes and transporters, which a play key role in drug metabolism and disposition in vivo. Pharmacokinetic interaction then takes place frequently, together with alteration in clinical outcome. The paper summarizes the pharmacokinetics and assessment approaches of herb-drug interaction, acting as a reference for practical use and research.

Key words: traditional Chinese medicine, drug interaction, pharmacokinetics, drug-metabolizing enzymes, transporter

CLC Number:

R969.7

HE Ji-chao, ZHOU Fang, ZHANG Jing-wei, YAN Ting-ting, WANG Guang-ji. Advancement in pharmacokinetic mechanisms of herb-drug interaction[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(4): 470-475.

References

[1] Voruganti S, Yamsani SK, Yamsani MR. Effect of silibinin on the pharmacokinetics of nitrendipine in rabbits[J]. Eur J Drug Metab Pharmacokinet, 2013.
[2] Schwarz UI, Hanso H, Oertel R, et al. Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol[J]. Clin Pharmacol Ther, 2007, 81(5):669-678.
[3] Hou YC, Lin SP, Chao PD. Liquorice reduced cyclosporine bioavailability by activating P-glycoprotein and CYP 3A[J]. Food Chem, 2012,135(4):2307-2312.
[4] Mandery K, Bujok K, Schmidt I, et al. Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1[J]. Biochem Pharmacol, 2010,80(11):1746-1753.
[5] Zhou F, Zhang J, Li P, et al. Toward a new age of cellular pharmacokinetics in drug discovery[J]. Drug Metab Rev, 2011,43(3):335-345.
[6] Zheng Y, Zhou F, Wu X, et al. 23-Hydroxybetulinic acid from Pulsatilla chinensis (Bunge) Regel synergizes the antitumor activities of doxorubicin in vitro and in vivo [J]. J Ethnopharmacol, 2010,128(3):615-622.
[7] Zhang J, Zhou F, Wu X, et al. Cellular pharmacokinetic mechanisms of adriamycin resistance and its modulation by 20(S)-ginsenoside Rh2 in MCF-7/Adr cells[J]. Br J Pharmacol, 2012,165(1):120-134.
[8] Zhang DM, He ZW, Liu XD, et al. In-vivo and in-vitro studies on the effect of Huang-Lian-Jie-Du-Tang on nimodipine transport across rat blood-brain barrier[J]. J Pharm Pharmacol, 2007,59(12):1733-1738.
[9] Taki Y, Yokotani K, Yamada S, et al. Ginkgo biloba extract attenuates warfarin-mediated anticoagulation through induction of hepatic cytochrome P450 enzymes by bilobalide in mice[J]. Phytomedicine, 2012,19(2):177-182.
[10] Malati CY, Robertson SM, Hunt JD, et al. Influence of Panax ginseng on cytochrome P450 (CYP)3A and P-glycoprotein (P-gp) activity in healthy participants[J]. J Clin Pharmacol, 2012,52(6):932-939.
[11] Goey AK, Meijerman I, Rosing H, et al. The effect of St John's wort on the pharmacokinetics of docetaxel[J]. Clin Pharmacokinet, 2014,53(1):103-110.
[12] Xia CH, Sun JG, Wang GJ, et al. Herb-drug interactions: in vivo and in vitro effect of Shenmai injection, a herbal preparation, on the metabolic activities of hepatic cytochrome P450 3A1/2, 2C6, 1A2, and 2E1 in rats[J]. Planta Med, 2010,76(3):245-250.
[13] Yamaura K, Shimada M, Nakayama N, et al. Protective effects of goldenseal (Hydrastis canadensis L.) on acetaminophen-induced hepatotoxicity through inhibition of CYP2E1 in rats[J]. Pharmacognosy Res, 2011,3(4):250-255.
[14] Hao H, Zheng X, Li P, et al. Translational research insights into pharmacokinetic herb-drug interactions[J]. Curr Drug Metab, 2011,12(9):850-870.
[15] Na DH, Ji HY, Park EJ, et al. Evaluation of metabolism-mediated herb-drug interactions[J]. Arch Pharm Res, 2011,34(11):1829-1842.
[16] Rengelshausen J, Banfield M, Riedel KD, et al. Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics[J]. Clin Pharmacol Ther, 2005,78(1):25-33.
[17] Lai L, Hao H, Wang Q, et al. Effects of short-term and long-term pretreatment of Schisandra lignans on regulating hepatic and intestinal CYP3A in rats[J]. Drug metab Dispos, 2009,37(12):2399-2407.
[18] Eberl S, Renner B, Neubert A, et al. Role of p-glycoprotein inhibition for drug interactions: evidence from in vitro and pharmacoepidemiological studies[J]. Clin Pharmacokinet, 2007,46(12):1039-1049.
[19] Xu R, Zhang X, Yang J, et al. Effects of glycyrrhizin on biliary transport and hepatic levels of glutathione in rats[J]. Biopharm Drug Dispos, 2012,33(5):235-245.
[20] de Lima Toccafondo Vieira M, Huang SM. Botanical-drug interactions: a scientific perspective[J]. Planta Med, 2012,78(13):1400-1415.
[21] Alissa EM. Medicinal Herbs and Therapeutic Drugs Interactions[J]. Ther Drug Monit, 2014.
[22] Brantley SJ, Argikar AA, Lin YS, et al. Herb-drug interactions: challenges and opportunities for improved predictions[J]. Drug Metab Dispos, 2014,42(3):301-317.
[23] Yan Z, Caldwell GW. In vitro identification of cytochrome P450 enzymes responsible for drug metabolism[J]. Methods Mol Biol, 2013,1015:251-261.
[24] Kwatra D, Budda B, Vadlapudi AD, et al. Transfected MDCK cell line with enhanced expression of CYP3A4 and glycoprotein as a model to study their role in drug transport and metabolism[J]. Mol Pharm, 2012,9(7):1877-1886.
[25] Vieira ML, Zhao P, Berglund EG, et al. Predicting drug interaction potential with a physiologically based pharmacokinetic model: a case study of telithromycin, a time-dependent CYP3A inhibitor[J]. Clin Pharmacol Ther, 2012,91(4):700-708.
[26] Zhao P, Zhang L, Grillo JA, et al. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review[J]. Clin Pharmacol Ther, 2011,89(2):259-267.
[27] Khalil F, Laer S. Physiologically based pharmacokinetic modeling: methodology, applications, and limitations with a focus on its role in pediatric drug development[J]. J Biomed, 2011,2011:907461.
[28] Dong X, Guan J, English JC, et al. Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy[J]. Clin Cancer Res, 2010,16(5):1442-1451.
[29] Moro M, Bertolini G, Tortoreto M, et al. Patient-derived xenografts of non small cell lung cancer: resurgence of an old model for investigation of modern concepts of tailored therapy and cancer stem cells[J]. J Biomed Biotechnol,2012,2012:568567.
[30] Stewart NA, Buch SC, Conrads TP, et al. A UPLC-MS/MS assay of the “Pittsburgh cocktail”: six CYP probe-drug/metabolites from human plasma and urine using stable isotope dilution[J]. Analyst, 2011,136(3):605-612.
[31] Chen XW, Sneed KB, Pan SY, et al. Herb-drug interactions and mechanistic and clinical considerations[J]. Curr Drug Metab, 2012,13(5):640-651.
[32] Videau O, Delaforge M, Levi M, et al. Biochemical and analytical development of the CIME cocktail for drug fate assessment in humans[J]. Rapid Commun Mass Spectrom, 2010,24(16):2407-2419.
[33] Videau O, Pitarque S, Troncale S, et al. Can a cocktail designed for phenotyping pharmacokinetics and metabolism enzymes in human be used efficiently in rat [J] ? Xenobiotica, 2012,42(4):349-354.
[34] Gurley BJ. Pharmacokinetic herb-drug interactions (part 1): origins, mechanisms, and the impact of botanical dietary supplements[J]. Planta Med, 2012,78(13):1478-1489.
[35] Huang SM, Temple R, Throckmorton DC, et al. Drug interaction studies: study design, data analysis, and implications for dosing and labeling[J]. Clin Pharmacol Ther, 2007,81(2):298-304.
[36] 陈群, 徐喆, 孙华, 等. 孕烷X受体生物特性及其在药物代谢中的作用研究进展[J]. 中国临床药理学与治疗学, 2013,18(3):241-246.
[37] Wu JJ, Ai CZ, Liu Y, et al. Interactions between phytochemicals from traditional Chinese medicines and human cytochrome P450 enzymes[J]. Curr Drug Metab, 2012,13(5):599-614.
[38] Zhang J, Zhou F, Lu M, et al. Pharmacokinetics-pharmacology disconnection of herbal medicines and its potential solutions with cellular pharmacokinetic-pharmacodynamic strategy[J]. Curr Drug Metab, 2012,13(5):558-576.